Oncopeptides publishes the 2022 annual report
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022 Annual Report has been published.
2022 was a landmark year for Oncopeptides. The company received a full marketing authorization for Pepaxti in Europe and initiated a launch of the drug in Germany. The commercialization enables us to bring hope to patients with multiple myeloma who despite the introduction of novel therapies need an accessible treatment option that offers robust efficacy, reduces treatment burden, and maintains quality of life.
“Since starting as CEO in January 2023, I have been impressed by our driven, experienced team and excited about the opportunity we have with Pepaxti. As we move forward, we have clear corporate goals which are aligned to our value drivers,” says Monica Shaw, CEO, Oncopeptides. “Our key priority for 2023 is to raise awareness and willingness to prescribe Pepaxti and ensure that we have the financial discipline needed to maximize our investments. “
The 2022 Annual Report is available as a pdf document on the website under Financial reports.
For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28
This information is information that Oncopeptides is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-25 11:15 CEST.
About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.
